NCT00664898View on ClinicalTrials.gov

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 8, 2010

Study Completion Date

April 8, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

bortezomib

Escalating intravenous repeating dose

DRUG

SGN-40

Escalating intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Genentech, Inc.

INDUSTRY